News

NeurogesX has announced that FDA agreed to its proposed study to evaluate Qutenza in patients with post-herpetic neuralgia (PHN) following pretreatment with an FDA approved topical anesthetic.  

Roche has reported that up to 56% of patients with active rheumatoid arthritis (RA) treated with ACTEMRA for over two years, will achieve disease remission. The new data

Roche has announced one year data from the two year Phase III LITHE study. The study demonstrated that a greater proportion of rheumatoid arthritis (RA) patients treated with

Altus has initiated patient dosing in phase-II trial for ALTU-238 in growth hormone deficiency pediatric subjects. ALTU-238 is a long-acting, extended release formulation of recombinant human growth hormone.

Boehringer Ingelheim presented new data at the Movement Disorder Society’s 13th International Congress of Parkinson’s Disease and Movement Disorders (MDS). The new results confirms high therapeutic benefit of

MDS Nordion, a provider of medical isotopes and radiopharmaceuticals, has announced that it has commenced the manufacture of CardioGen-82 (Rubidium-82 generators), for Bracco. MDS Nordion has designed and

AEterna Zentaris has initiated an extended study in the Phase-III program with cetrorelix pamoate, for the treatment of benign prostatic hyperplasia (BPH). Cetrorelix pamoate is currently in three

Metabasis and its partner Merck have announced that AMP protein kinase (AMPK) activators, has yielded a lead candidate that Merck has selected to advance into late preclinical development.

Osteotech has announced that it has completed enrollment for the clinical trial of DuraTech BioRegeneration Matrix. DuraTech, used to repair dura mater during cranial surgical procedures, is based